公司概覽
業務類別 Biotechnology
業務概覽 Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
公司地址 3611 Valley Centre Drive, Suite 300, San Diego, CA, USA, 92130
電話號碼 +1 888 969-7879
傳真號碼 --
公司網頁 https://www.travere.com
員工數量 497
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Elizabeth E. Reed Chief Legal Officer, General Counsel and Corporate Secretary -- 06/04/2026
Dr. William E. Rote, PhD Chief Research Officer 美元 522.33K 16/06/2026
Dr. Eric M. Dube, PhD Director, President and Chief Executive Officer 美元 854.25K 21/09/2026
Mr. Peter Heerma Chief Commercial Officer 美元 527.92K 06/04/2026
Ms. Sandra Calvin Senior Vice President and Chief Accounting Officer -- 09/07/2026
Dr. Jula Inrig, M.D. Executive Vice President, Head of Research & Development and Chief Medical Officer 美元 568.08K 16/06/2026
Mr. Christopher Cline Chief Financial Officer 美元 522.92K 06/04/2026
Mr. John Torell Vice President and Controller -- 09/07/2026
 
董事會成員
董事會 職務 更新日期
Mr. Gary A. Lyons Chairman of the Board 06/04/2026
Mr. Ron Squarer Independent Director 06/04/2026
Mr. Timothy P. Coughlin Independent Director 06/04/2026
Mr. John A. Orwin, M.B.A. Independent Director 06/04/2026
Dr. Suzanne L. Bruhn, PhD Independent Director 06/04/2026
Mr. Jeffrey A. Meckler Independent Director 06/04/2026
Ms. Sandra E. Poole Independent Director 06/04/2026
Dr. Roy D. Baynes, M.D.,PhD Independent Director 06/04/2026
Dr. Eric M. Dube, PhD Director, President and Chief Executive Officer 21/09/2026
Ms. Ruth Williams-Brinkley Independent Director 06/04/2026
 
所屬ETF (更新日期: 14/11/2026 03:27)
代號 名稱 佔比% ▼ 持有日期
ONEQFidelity Nasdaq Composite ETF0.02%30/10/2026
JHSCJHancock Multifactor Small Cap ETF0.02%30/10/2026
FADFirst Trust Multi Cap Gr AlphaDEX® ETF0.02%29/10/2026
IWViShares Russell 3000 ETF0.02%30/10/2026
FSCCFederated Hermes MDT Small Cap Core ETF0.02%30/10/2026
HELXFranklin Genomic Advancements ETF0.02%31/10/2026
CTAGCalamos Timpani Active SMID Growth ETF0.02%31/07/2026
SEISSEI Select Small Cap ETF0.01%30/10/2026
MMSCFirst Trust Multi-Manager Sm Cp Opps ETF0.01%29/10/2026
AFMCFirst Trust Active Factor Mid Cap ETF0.01%29/10/2026
FHEQFidelity Hedged Equity ETF0.01%30/10/2026
GRXGabelli Health & Wellness0.01%30/06/2026
SPITF/m Emerald Special Situations ETF0.01%30/10/2026
VTHRVanguard Russell 3000 ETF0.01%30/09/2026
SCHKSchwab 1000 ETF0.01%31/10/2026
AFSMFirst Trust Active Factor Small Cap ETF0.01%29/10/2026
IBBQInvesco Nasdaq Biotechnology ETF0.01%30/10/2026
RUSCRussell Inv U.S. Small Cap Equity ETF0.01%31/10/2026
ITWOProShares Russell 2000 High Income ETF0.01%30/10/2026
WSMLiShares MSCI World Small-Cap ETF0.01%30/10/2026
  1    2   3    4    5    6  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.